This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

2 Mar 2011

NeuroPhage Secures $12.4M for Alzheimer's Disease Treatment

NeuroPhage Pharmaceuticals announced that it has secured $12.4 million in Series B financing, which will be mostly directed to the development for the treatment of Alzheimer's disease.

Cambridge, MA-based NeuroPhage Pharmaceuticals has closed $12.4 million in new venture funding to support a Phase I trial of its lead therapy for Alzheimer's disease. Two new investors, MerieuxDeveloppement and Shire, both contributed to the Series B, which brings the fledgling biotech's total venture haul to $19.6 million.


The upstart biotech has been working on a "protein disaggregation" platform which was hatched in the lab of Professor Beka Solomon, Chair for Biotechnology of Neurodegenerative Diseases at Tel Aviv University. NeuroPhage believes that it

Related News